VIVANET, GRAZIA
VIVANET, GRAZIA
Universita' degli Studi di MILANO
Primary malignant phyllodes tumors of the breast: A retrospective analysis from a referral center
2024 C. Valenza, T.M. De Pas, A. Gaeta, G. Castellano, C. Santoro, A. Corona, G. Chiappini, G. Vivanet, D. Trapani, S. Coppola, F. Conforti, D. Mattar, S. Gandini, P. Veronesi, E. Pennacchioli, G. Curigliano
High-dose continuous-infusion ifosfamide in advanced thymic epithelial Tumors: A TYME network study
2023 F. Conforti, L. Pala, G. Vivanet, C. Corti, C. Catania, D. Maiettini, G. Varano, B. Di Venosa, G. Curigliano, P. Salvini, R. Berardi, Z. Ballatore, T.M. De Pas
High-Dose Ifosfamide for advanced thymic epithelial tumors (TETs): a TYME network study
2022 G. Vivanet, C. Corti, F. Conforti, P. Zucali, M. Perrino, R. Berardi, Z. Ballatore, C. Catania, L. Pala, G. Curigliano, D. Maiettini, B. Di Venosa, T. De Pas
A set of easy and stringent criteria to identify immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1-2 trial population
2022 L. Mazzarella, F. Giugliano, E. Nicolo', E. Crimini, J. Uliano, C. Corti, P. D'Amico, P. Aliaga, C. Valenza, M. Repetto, G. Antonarelli, L. Ascione, G. Vivanet, P. Giachetti, I. Minchella, C. Belli, A. Esposito, M. Locatelli, C. Criscitiello, G. Curigliano
Evolution of low HER2 expression between early and advanced-stage breast cancer
2022 P. Tarantino, S. Gandini, E. Nicolo, P. Trillo, F. Giugliano, P. Zagami, G. Vivanet, F. Bellerba, D. Trapani, A. Marra, A. Esposito, C. Criscitiello, G. Viale, G. Curigliano
SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis
2022 F. Giugliano, P.A. Zucali, G. Galli, Z. Ballatore, C. Corti, P.T. Aliaga, J. Uliano, G. Vivanet, G. Curigliano, F. Conforti, P. Queirolo, R. Berardi, S. Manglaviti, G. Apollonio, M. Perrino, F. Borea, F. D'Antonio, M.C. Garassino, T. De Pas
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials
2021 P. Trillo Aliaga, D. Trapani, J.L. Sandoval, E. Crimini, G. Antonarelli, G. Vivanet, S. Morganti, C. Corti, P. Tarantino, A. Friedlaender, C. Belli, I. Minchella, M. Locatelli, A. Esposito, C. Criscitiello, G. Curigliano
COVID-19 related risk in patients enrolled in early-phase clinical trials
2021 P. D'Amico, P. Trillo, S. Morganti, C. Corti, G. Vivanet, E. Crimini, L. Ascione, P. Tarantino, G. Antonarelli, M. Locatelli, A. Esposito, C. Belli, G. Curigliano
Immune-related adverse events are correlated with significantly improved outcome in a phase I trial population exposed to combination immunotherapy
2021 L. Mazzarella, F. Giugliano, E. Crimini, J. Uliano, C. Corti, P. D'Amico, P. Aliaga, C. Valenza, M. Repetto, E. Nicolo, G. Antonarelli, L. Ascione, G. Vivanet, P. Giachetti, C. Belli, C. Criscitiello, A. Esposito, M. Locatelli, I. Minchella, G. Curigliano